Cargando…

Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan

INTRODUCTION: The insufficient quantity and quality of clinical epidemiological evidence in the field of rare diseases have posed methodological challenges to develop clinical practice guidelines (CPGs). Guideline development groups struggle to provide patients and their families with beneficial gui...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchida, Tomoe, Takahashi, Yoshimitsu, Yamashita, Hiromitsu, Nakaoku, Yuriko, Ohura, Tomoko, Okura, Takashi, Masuzawa, Yuko, Hosaka, Masayoshi, Kobayashi, Hiroshi, Sengoku, Tami, Nakayama, Takeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646292/
https://www.ncbi.nlm.nih.gov/pubmed/36407062
http://dx.doi.org/10.31662/jmaj.2022-0094
_version_ 1784827131802419200
author Uchida, Tomoe
Takahashi, Yoshimitsu
Yamashita, Hiromitsu
Nakaoku, Yuriko
Ohura, Tomoko
Okura, Takashi
Masuzawa, Yuko
Hosaka, Masayoshi
Kobayashi, Hiroshi
Sengoku, Tami
Nakayama, Takeo
author_facet Uchida, Tomoe
Takahashi, Yoshimitsu
Yamashita, Hiromitsu
Nakaoku, Yuriko
Ohura, Tomoko
Okura, Takashi
Masuzawa, Yuko
Hosaka, Masayoshi
Kobayashi, Hiroshi
Sengoku, Tami
Nakayama, Takeo
author_sort Uchida, Tomoe
collection PubMed
description INTRODUCTION: The insufficient quantity and quality of clinical epidemiological evidence in the field of rare diseases have posed methodological challenges to develop clinical practice guidelines (CPGs). Guideline development groups struggle to provide patients and their families with beneficial guidance, such as that for medical care and in complex circumstances. Motivated by the challenges, we focused on information on resources for supporting the daily and social life to improve the CPGs for users. We aimed to assess the methodological quality of CPGs for rare diseases in Japan and to evaluate information on resources to support the daily and social life in the CPGs. METHODS: We conducted a systematic search using PubMed, three electronic Japanese databases, and two hand-searched sources in Japan. The Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument with six domains was used to assess the methodological quality of the CPGs. A content analysis of the CPG text was conducted using five keywords as information on non-medical resources, e.g., “Intractable Disease Consultation Support Center,” “Japan Intractable Disease Information Center,” and “Patient Association.” RESULTS: A total of 55 CPGs met the inclusion criteria. Among four domains of AGREE II with low scores (Stakeholder Involvement, Rigor of Development, Applicability, and Editorial Independence), Rigor of Development had the lowest median score. As for information on non-medical resources, 41 CPGs included at least 1 of the 5 keywords, while 14 CPGs included none. CONCLUSIONS: At the Rigor of Development domain, methodological challenges may have resulted in an insufficient description of items regarding the translation evidence to recommendations. As the sufficiency of five keywords as information on non-medical resources could be improved, the information will be advocative as clues to provide pragmatic guidance, particularly for rare diseases with limited medical evidence.
format Online
Article
Text
id pubmed-9646292
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japan Medical Association
record_format MEDLINE/PubMed
spelling pubmed-96462922022-11-18 Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan Uchida, Tomoe Takahashi, Yoshimitsu Yamashita, Hiromitsu Nakaoku, Yuriko Ohura, Tomoko Okura, Takashi Masuzawa, Yuko Hosaka, Masayoshi Kobayashi, Hiroshi Sengoku, Tami Nakayama, Takeo JMA J Original Research Article INTRODUCTION: The insufficient quantity and quality of clinical epidemiological evidence in the field of rare diseases have posed methodological challenges to develop clinical practice guidelines (CPGs). Guideline development groups struggle to provide patients and their families with beneficial guidance, such as that for medical care and in complex circumstances. Motivated by the challenges, we focused on information on resources for supporting the daily and social life to improve the CPGs for users. We aimed to assess the methodological quality of CPGs for rare diseases in Japan and to evaluate information on resources to support the daily and social life in the CPGs. METHODS: We conducted a systematic search using PubMed, three electronic Japanese databases, and two hand-searched sources in Japan. The Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument with six domains was used to assess the methodological quality of the CPGs. A content analysis of the CPG text was conducted using five keywords as information on non-medical resources, e.g., “Intractable Disease Consultation Support Center,” “Japan Intractable Disease Information Center,” and “Patient Association.” RESULTS: A total of 55 CPGs met the inclusion criteria. Among four domains of AGREE II with low scores (Stakeholder Involvement, Rigor of Development, Applicability, and Editorial Independence), Rigor of Development had the lowest median score. As for information on non-medical resources, 41 CPGs included at least 1 of the 5 keywords, while 14 CPGs included none. CONCLUSIONS: At the Rigor of Development domain, methodological challenges may have resulted in an insufficient description of items regarding the translation evidence to recommendations. As the sufficiency of five keywords as information on non-medical resources could be improved, the information will be advocative as clues to provide pragmatic guidance, particularly for rare diseases with limited medical evidence. Japan Medical Association 2022-09-30 2022-10-17 /pmc/articles/PMC9646292/ /pubmed/36407062 http://dx.doi.org/10.31662/jmaj.2022-0094 Text en Copyright © Japan Medical Association https://creativecommons.org/licenses/by/4.0/JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Original Research Article
Uchida, Tomoe
Takahashi, Yoshimitsu
Yamashita, Hiromitsu
Nakaoku, Yuriko
Ohura, Tomoko
Okura, Takashi
Masuzawa, Yuko
Hosaka, Masayoshi
Kobayashi, Hiroshi
Sengoku, Tami
Nakayama, Takeo
Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan
title Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan
title_full Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan
title_fullStr Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan
title_full_unstemmed Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan
title_short Evaluation of Clinical Practice Guidelines for Rare Diseases in Japan
title_sort evaluation of clinical practice guidelines for rare diseases in japan
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646292/
https://www.ncbi.nlm.nih.gov/pubmed/36407062
http://dx.doi.org/10.31662/jmaj.2022-0094
work_keys_str_mv AT uchidatomoe evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT takahashiyoshimitsu evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT yamashitahiromitsu evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT nakaokuyuriko evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT ohuratomoko evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT okuratakashi evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT masuzawayuko evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT hosakamasayoshi evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT kobayashihiroshi evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT sengokutami evaluationofclinicalpracticeguidelinesforrarediseasesinjapan
AT nakayamatakeo evaluationofclinicalpracticeguidelinesforrarediseasesinjapan